



Attorney Docket No. 59572(46865)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**APPLICANT:** Thomas J. Jentsch  
**U.S.S.N.:** 10/622,377 **ART UNIT:** 1645  
**FILED:** July 18, 2003 **EXAMINER:** Not Yet Known  
**FOR:** TEST SYSTEM FOR THE DEVELOPMENT OF THERAPEUTIC AGENTS, IN PARTICULAR ACTIVE COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS

**CERTIFICATE OF MAIL**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: **MAIL STOP MISSING PARTS**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **May 20, 2004**.

By: 

Donna R. Davis

**MAIL STOP MISSING PARTS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

**REQUEST FOR CORRECTION OF FILING RECEIPT**

Applicant respectfully requests a corrected Filing Receipt for the above-referenced patent application. Specifically, Applicant requests that the following change(s) be made:

The correct title of the application is: "**TEST SYSTEM FOR THE DEVELOPMENT OF THERAPEUTIC AGENTS, IN PARTICULAR ACTIVE COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS**"


A copy of the Filing Receipt is enclosed with the requested changes and/or additions underlined in red ink.

Applicant(s) believe that no fees are required. However, if for any reason a fee is required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 04-1105.

If the enclosed papers are considered incomplete, the mailroom and/or the Application Branch is respectfully requested to contact the undersigned at (617) 439-4444, Boston, Massachusetts.

Respectfully submitted,

By:

  
\_\_\_\_\_  
Gregory B. Butler, Ph.D., Esq.

Reg. No.: 34,558

EDWARDS & ANGELL, LLP

P.O. Box 55874

Boston, Massachusetts 02205

Tel.: 617-439-4444

Fax: 617-439-4170

Customer No.: 21874

Date: May 20, 2004




## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov


APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/622,377	07/18/2003	1645	0.00	46865/59572	1	16	3

Edwards & Angel, LLP  
Intellectual Property Practice Group  
P.O. Box 55874  
Boston, MA 02205



CONFIRMATION NO. 9926

## FILING RECEIPT



OG000000012191821\*

Date Mailed: 03/25/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Thomas J. Jentsch, Residence Not Provided;

## Domestic Priority data as claimed by applicant

This application is a CON of PCT/DK02/00038 01/17/2002

## Foreign Applications

GERMANY 101 02 977.2 01/23/2001

If Required, Foreign Filing License Granted: 03/24/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

## Title

Animal model and cell-line expressing modified chlorine channel

## Preliminary Class

Correct title to:

TEST SYSTEM FOR THE DEVELOPMENT OF  
THERAPEUTIC AGENTS, IN PARTICULAR ACTIVE  
COMPOUNDS FOR THE TREATMENT OF  
OSTEOPOROSIS

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).